
KAMADA LTD
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Kamada Ltd. develops, manufactures, and markets plasma-derived and other biopharmaceutical protein therapeutics, including treatments for alpha-1 antitrypsin deficiency, rabies, and other immune-related conditions, and also provides plasma collection services.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Tsur DavidDirector | Sell | $1.34M | 162,760at $8.26 | Sep 8, 2026 |
| Tsur DavidDirector | Sell | $118K | 14,238at $8.28 | Sep 7, 2026 |
| Tsur DavidDirector | Sell | $1K | 175at $8.26 | Sep 9, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable KMDA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.